MEDI-528, now recognized as enokizumab , represents a novel treatment targeting the IGF1R, a vital protein linked in multiple skin ailments. Early trial results suggest considerable promise for the https://ammarfunp132888.wikipresses.com/7470078/enokizumab_a_deep_dive_into_medi_528_and_its_potential